Dr Jeremy Ramsden
studied natural sciences at the University of Cambridge, received his doctorate from EPFL. Postdoctoral studies at Princeton University, member of the faculty of natural philosophy of Basel University, subsequently Professor and Chair of Nanotechnology at Cranfield University, and Director of Bionanotechnology at Cranfield University at Kitakyushu. Visiting professor in Argentina, France, Georgia, Hungary and Japan. Jeremy has published some 300 research articles as well as books on nanotechnology, bioinformatics etc. In the last few years he has co-founded several high-tech companies developing nanomaterials and nanodevices. Hon. Professor of Nanotechnology at the University of Buckingham, Fellow of the Institute of Materials, Minerals and Mining (IoM3) in London, a IUPAC Fellow, and chairs the Resources Strategy Group of IoM3.
Anna Stenstam
is CEO and co-founder of CR Competence. She has a PhD in physical chemistry, and the team at CR is focused on providing business advice based on fundamental understanding of chemistry. Anna was awarded Honorary Doctor at the faculty of Engineering at Lund University for her work to realize academic-industrial relations into tangible results. She is also a member of the external advisory board of NanoLund and the steering committee of MyFab, the Swedish national research infrastructure for micro and nanofabrication where she is an experienced board member. She is an international expert at technical due diligence in relation to advanced methods and has deep understanding of ingredients, products and processes available through biotechnology and nanoscience.
John Mayo CBE
has a 35 year track record of advising on, initiating, structuring, and executing creative business transactions, and of managing large listed groups, private equity funds and their underlying businesses through growth, reorganisation, restructuring, value release and if required, exit. For example: John was responsible for the spin-out of Zeneca from ICI and its subsequent merger with Astra to form AstraZeneca. By the time he left AZ four years later, the market cap of the organisation had increased from $9b to $30b. Since 2001, John has founded and grown several private businesses including Beehive Capital plc, an FCA regulated investment banking boutique that advises high-growth healthcare companies and private equity portfolios. He has served as an executive director at Zeneca Group plc (now AZ), GEC plc, and numerous private companies and as non-executive director on the boards of Schlumberger, Alstom, Newcastle United and Pentland, on the advisory board of BHF Bank and the Supervisory Board of IDEA AG. On 31 December 1999, John was made a Commander of the British Empire (CBE) in recognition of his services to British Industry. John is a UK citizen and is based in London.
Dr Alec Reader
was recently Director of Micro & Nanotechnology Knowledge Transfer Network for the UK government. Has 30 years-experience in micro and nano-electronics industries commercialising emerging technologies. Alec has been instrumental in driving investor value with prominent positions within Philips Analytical (Semiconductors). He was a Head of Department at ST-Microelectronics in France, a post– doctoral fellow at Delft Technical University and spent about 20 years at Philips Research in Eindhoven. Also managing over €150m in projects across Europe related to nanotechnology commercialisation. Achievements include 140 published technical papers and has a PhD in Science of Materials (solid state physics). He has been instrumental in a number of start-ups which have since exited to large global conglomerates after developing significant revenues and value for their shareholders. More recently led developments for Micro-Systems for Samsung as well as micro-fluidics-based systems for PCR testing instruments. Has recently advised on lateral flow testing devices as well as rapid COVID-19 testing for Abbot Rapid Diagnostics.
Dr Denis Koltsov
is Chairman of international standards for ISO. Nanotechnology professional with background in Physics and Engineering specialising in innovation, research, Nanotechnology competitor analysis, technology scouting, market research, standardisation and scaling in nanotechnology related sectors. Research interests are in nanomaterials characterisation, dispersion stability, fine bubbles technology, novel applications and product development, process optimisation and strategy for innovation. I also provide bespoke intelligence reports, independent technology evaluations and market surveys in the area of nanotechnology or nanomaterials. Denis is the founder of BREC Solutions which is a technology consulting company specialising in innovation, research, training and funding bids. They build teams of experts for clients and run research and development projects to develop solutions for market research, competitor analysis, cost optimisation, process streamlining, product development, strategy implementation, restructuring and interim management.
Dr Naz Bashir
has a PhD/MBA in Chemistry and he is currently Founder of Evolutia Venture partners who specialise in supporting investments from life sciences, biotech, med-tech, artificial intelligence and health-tech disciplines. He has international experience in developing point of care technology using nanoscale technologies. He is also non-exec director of AlgaeCytes a nutraceuticals company developing an algae-based bio refining process to produce Omega 3 oils sustainably. He is also Trustee for UK based charity World Science Aid. He has worked with a number of successful start-ups that have exited or created significant value for their shareholders. Previously manager for technology transfer for world leading university of Surrey previously home to Nobel Prize winner Harry Kroto for nanotechnology.
Dr Tommy Dolan
is former Vice President and board member at Pfizer in Worldwide Medicinal Sciences. Formerly Site Head for the Pfizer European HQ. Led the design and development of all small molecule medicinal products for Pfizer R&D globally. Lead scientist for the team that developed Viagra. Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde studying novel drug carriers. This followed researching novel hydrogels as controlled drug delivery systems. He is a past Chair of the UK Academy of Pharmaceutical Sciences, a present member of the UK Academy of Pharmaceutical Sciences Advisory Board and visiting Professor at the School of Pharmacy University College London. He was a former member of: the UK Medicines Manufacturing Industry Partnership (MMIP) Steering Group, the EFPIA Innovation Business Steering Committee, and a Company Director on the Pfizer UK Ltd Board. He also holds a D.Sc. (honoris causa) from the University of Greenwich.
Richard King
is Managing Director at PDS Strategic Consulting and Chief Analyst for The World Nano Foundation. Head of the business intelligence unit for Nano Media Group and specialist in advising high growth Nanotechnology and biotech companies in Rating Strategic AmbitionTM and international scalability. Previously a senior executive advisor to pharma, aerospace and automotive conglomerates as well as start-ups. Richard has developed investment and technology modelling for healthcare technologies including diagnostics, medical devices and nano therapies. He has also developed an international model for accessing rapid testing for COVID-19 with its COVIDlyticsTM study into managing the transmission of the current virus in relation to asymptomatics found in the population. Has previously held senior management positions with Rolls-Royce and Rockwell International.
Olivier Jarry
has held senior positions with life science companies including Novartis, Bayer, Bristol-Myers Squibb globally managing multi-billion-dollar businesses for over 30 years. Specialisms include neuroimmunology, oncology, cell & gene therapy, and digital therapeutics in consumer health and nutrition technologies. Olivier is a FINRA registered (Series 7, 63, 79) investment banker in the US with Atlas Advisors. He has led strategy and concluded acquisitions, divestitures, and alliances, including the negotiation of several hundred million plus commercial agreements in the Americas, Europe, Russia, India, China and Japan. He has led the post-merger integration practice for Accenture in Europe with pre- and post-acquisition projects in the Americas and Europe in a variety of industries. As the CFO of Danone in North America, he has led several acquisitions including a $1.1 billion acquisition of a water related business. He holds a TRIUM executive MBA (NYU Stern, LSE London, HEC Paris), a MEng from the French DOD (Ingénieur de l’Armement) and a MSc from Ecole Centrale de Paris. He has deep connections in the healthcare space and investor community, which have allowed him to design collaboration agreements and plan exits.
